Denise Bronner, Ph.D., makes the case for and against acquisitions for rejuvenating Big Pharma pipelines. She explains why outsourcing innovation can be as risky, and costly, as internal discovery.

And while Trump has criticized Ireland for attracting big pharma companies, he’s also suggested he wants to reshore ...

Explore the impact of proposed Pharma tariffs on global markets as major stocks tumble. Click for my updated look at selected picks in the health industry.

Then this is an important and timely book for you, one written for the layman about the crisis in psychiatry and the near ...

Several market veterans are advicing investors not to be deterred by the volatility and stick to asset allocation, as a host ...

Big pharma, by contrast, is focused on how these ... If there is a problem, it is that these differing incentives mean that a lot of outstanding academic innovation never makes it to impact ...

The effectiveness of AI applications can be undermined by the volumes of unstructured data prevalent in the pharma industry ... upon the same foundation: Big Data. But a longstanding challenge ...

The following is the transcript of an interview with U.S. trade representative Jamieson Greer that aired on "Face the Nation ...

Sun Pharma Wins Legal Battle in US, What Does It Mean for Investors Zee Business Video Team | Updated: April 11, 2025 03:48 PM IST Sun Pharma has got a big relief from the US court, what is the whole ...